Prevention of Acute Chemotherapy-induced Death in Mice by Recombinant Human Interleukin 1: Protection from Hematological and Nonhematological Toxicities

Cancer Research

Volumn 52, Issue 15, 1992, Pages 4082-4089

  Futami, Hitoyasu ^a,f   Back, Timothy ^b   Keller, Jonathan R ^b   Wiltrout, Robert H ^a  

^a Laboratory of Experimental Immunology   (United States)

^b Biological Carcinogenesis and Development Program ^*  (United States)

^c Lab of Molecular Immunoregulation   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROETHYLNITROSOUREA; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; INTERLEUKIN 1;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; IMMUNE RESPONSE; LETHAL DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; BONE MARROW; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEATH; DOXORUBICIN; FLUOROURACIL; HEMATOPOIETIC STEM CELLS; HUMAN; INTERLEUKIN-1; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, NUDE; RECOMBINANT PROTEINS; SPLEEN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TUMOR NECROSIS FACTOR;

EID: 0026672643     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Chabner, B. A., and Myers, C. E. Clinical pharmacology of cancer chemotherapy. Im V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.). Cancer, Principles and Practice of Oncology, Ed. 3, pp. 349-395. Philadelphia: J. B. Lippincott Co., 1989.
2. Pizzo, P. A. Granulocytopenia and cancer therapy. Past problems, current solutions and future challenges. Cancer (Phila.), 54: 2649-2661, 1984.
3. Griswold, D. P., Jr., Trader, M. W., Frei, E., Peters, W. P., Wolpert, M. K., and Laster, W. R., Jr. Response of drug sensitive and resistant L1210 leukemias to high-dose chemotherapy. Cancer Res., 47: 2323-2327, 1987.
4. Dinarello, C. A. Interleukin-1 and its receptor. Crit. Rev. Immunol., 9:1-20, 1989.
5. Durum, S. K., Schmidt, J. A., and Oppenheim, J. J. Interleukin 1. An immunological perspective. Annu. Rev. Immunol., 3: 263-287, 1985.
6. Oppenheim, J. J., Kovacs, E. J., Matsushima, K., and Durum, S. K. There is more than one interleukin 1. Immunol. Today, 7:45-56, 1986.
7. Lachman, L. B. Human interleukin 1: purification and properties. Fed. Proc., 42: 2639-2645, 1985.
8. Moore, A. S. Role of interleukin-1 in hematopoiesis. Immunol. Res., 8: 165-175, 1989.
9. Neta, R., Vogel, S. N., Oppenheim, J. J., and Douches, S. D. Cytokines in radioprotection. Comparison of the radioprotective effects of ILl to IL2, GM-CSF and IFNa. Lymphokine Res., 5: 5105-5110, 1986.
10. Neta, R., Douches, S., and Oppenheim, J. J. Interleukin I as a radioprotector. J. Immunol., 136: 2483-2485, 1986.
11. Castelli, M. P., Black, P. L., Schneider, M., Pennington, R., Abe, F., and Talmadge, J. E. Protective restorative and therapeutic properties of recombinant human IL-1 in rodent models. J. Immunol., 140: 3830-3837, 1988.
12. Futami, H., Jansen, R., MacPhee, M. J., Keller, J., McCormick, K., Longo, D. L., Oppenheim, J. J., Ruscetti, F. W., and Wiltrout, R. H. Chemoprotective effects of rhIL-la in normal and tumor bearing mice: protection from acute toxicity, hematological effects, development of late mortality and enhanced therapeutic efHcacy. J. Immunol., 145:4121-4130, 1990.
13. Moore, M. A. S., and Warren, D. J. Synergy of interleukin 1 and granulocyte colony-stimulating factor in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc. Natl. Acad. Sci. USA, 84: 7134-7138, 1987.
14. Arika, S., Hirano, T., Toga, T., and Kishimoto, T. Biology of multifunctional cytokines IL-6 and related molecules (IL-1 and TNF). FASEB J., 4: 2860-2867, 1990.
15. Wong, C. G., and Clark, S. C. Multiple action of interleukin 6 within a cytokine network. Immunol. Today, 9: 137-141, 1990.
16. Hirano, T., Akira, S., Taga, T., and Kishimoto, T. Biological and clinical aspects of interleukin 6. Immunol. Today, 11:443-449, 1990.
17. L4ist-Bamey, K., Homon, C. A., Faanes, R. B., and Merluzzi, V. J. Synergistic and overlapping activities of tumor necrosis factor a and IL-1. J. Immunol., 141: 527-530, 1988.
18. Broudly, V. C., Kanshansky, K., Harlan, J. M., and Adamson, J. W. Interleukin 1 stimulates human endothelial cells to produce granulocyte-macroph-age colony-stimulating factor and granulocyte colony-stimulating factor. J. Immunol., 139: 464-468, 1987.
19. Sieff, C. A., Niemeyer, C. M., Mentzer, S. J., and Faller, D. V. Interleukin 1, tumor necrosis factor and the production of colony stimulating factors by cultured mesenchymal cells. Blood, 72: 1316-1323, 1988.
20. Kanshansky, K., Lin, N., and Adamson, J. W. Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors. J. Clin. Invest., 81: 92-97, 1988.
21. Vogel, S. N., Douches, S. D., Kaufman, E. N., and Neta, R. Induction of colony stimulating factor in vivo by recombinant IL-1 a and recombinant TNFa. J. Immunol., 138: 2143-2148, 1987.
22. Shalaby, M. R., Waage, A., Aarden, L., and Espevik, T. Endotoxin, tumor necrosis factor a and interleukin 1 induce interleukin 6 production in vivo. Clin. Immunol. Immunopathol., 51: 488-498, 1989.
23. Dinarello, C. A. Interleukin 1 and its Biologically related cytokines. Adv. Immunol., 44: 153-205, 1989.
24. Libert, C., Brouckaert, P., Shaw, A., and Fiers, W. Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice. Eur. J. Immunol., 20:691-694, 1990.
25. Flick, D. A., and Gifford, G. E. Production of tumor necrosis factor in unprimed mice: mechanism of endotoxin-mediated tumor necrosis. ImmunoBiology, 171: 320-328, 1986.
26. Valiteri, M., Tweardy, D. J., Caracciolo, D., Johnson, K., Mavilio, F., Alt-mann. S., Santoli, D., and Rovera, G. Cytokine-dependent granulocytic differentiation: regulation of proliferative and differentiative responses in a murine progenitor cell line. J. Immunol., 138: 3829-3835, 1987.
27. Tiris, R. G., Sherry, B., and Ceramy, A. The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites. Immunol. Today, 12: A13-A16, 1991.
28. Stinner, G., and Floersheim, G. L. Bone marrow transplantation after lethal chemotherapy in “nude mice.” Transplantation (Baltimore), 24: 218-222, 1977.
29. Gallicchio, V. S., Shedlofsky, S. I., Swim, A. T., Robinson, J. M., Hulette, B. C., Messino, M. T., and Doukas, M. A. Modulation of murine hematopoiesis in vivo with recombinant murine interleukin 1. J. Biol. Response Modif., 8: 422-439, 1989.
30. Broxmeyer, H. E., and Vadhan-Raj, S. Preclinical and clinical studies with the hematopoietic colony stimulating factors and related interleukins. Immunol. Res., 8: 185-201, 1989.
31. Calvert, A. M., Harlard, S. J., Newell, D. R., Siddik, Z. M., Jones, A. C., McElwain, T. J., Rajn, S., Wiltshaw, E., Smith, I. E., Baker, J. M., Peckham, M. J., and Harrap, K. R. Early clinical studies with ci5-diammine-l,l-cyclob-utane dicarboxylate platinum (11). Cancer Chemother. Pharmacol., 9:140-147, 1982.
32. Evans, B. D., Rajn, K. S., Calvert, A. H., Harland, S. J., and Wiltshaw, E. Phase II study of JM8 a new platinum analog in advanced ovarian carcinoma. Cancer Treat. Rep., 67:997-1000, 1984.
33. Takatsuki, F., Okano, A., Suzuki, C., Miyasaka, V., Hirano, T., Kishimoto, T., Ejima, D., and Akiyama, Y. Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Canccr Res., 50: 2885-2890, 1990.
34. Neta, R., Oppenheim, J. J., and Douches, S. Interdependence of the radioprotective effects of human recombinant interleukin la, tumor necrosis factor a., granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony stimulating factor. J. Immunol., 140: 108-111, 1988.
35. Neta, R., Sztein, M. B., Oppenheim, J. J., Gillis, S., and Douches, S. D. The in vivo Effects of interleukin 1.1. Bone marrow cells are induced to cycle after administration of interleukin 1. J. Immunol., 139: 1861-1866, 1987.
36. Fibbe, W. E., Van der Meer, J. W. M., Frederik Falkenburg, J. H., Hamilton, M. S., Kluin-Neleman, J. C., and Dinarello, C. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp. Hematol., 17: 805-808, 1989.
37. Prestayko, A. W., Baker, L. H., Crooke, S. T., Carter, S. K., and Schein, P. S. (eds.). Nitrosoureas. Current Status and New Developments. New York: Academic Press, 1981.
38. Eppstein, D. A., Kurakara, C. G., Bruno, N. A., and Ferrell, T. G. Prevention of doxorubicin-induced hematotoxicity in mice with interleukin I. Cancer Res., 49: 3955-3960, 1989.
39. Dorshkind, K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu. Rev. Immunol., 8: 111-137, 1990.
40. O'Connell, T. X., and Berenbaum, M. C. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res., 34: 1568-1591, 1974.
41. Aisenberg, A. C., and Wilkes, B. Immunological tolerance induced by cyclophosphamide assayed by plaque spleen cell method. Nature (Lond.), 213: 498-499, 1967.
42. Ozaki, Y., Ohashi, T., Minami, A., and Nakamura, S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-la. Infect. Immun., 55: 1436-1440, 1987.
43. Mier, J. W. M., Barza, M., Wolff, S. M., and Dinarello, C. A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc. Natl. Acad. Sci. USA, 85: 1620-1623, 1988.
44. Moritage, T., Mizushima, Y., Sakamoto, K., and Yano, S. Prevention of fatal infections by recombinant interleukin la in normal and anticancer drug-treated mice. Cancer Res., 50: 2099-2104, 1990.
45. Minami, A., Fujimoto, K., Ozaki, Y., and Nakamura, S. Augmentation of host resistance to microbial infections by recombinant human interleukin la. Infect. Immun., 56: 3116-3120, 1988.
46. Gauldie, J., Richards, C., Hamish, D., Landsdorp, P., and Baumann, H. Interferon ß2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the miyor acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA, 84: 7251-7255, 1987.
47. Broxmeyer, H. E., Williams, D. E., Lu, L., Cooper, S., Anderson, S. L., Beyer, G. S., Hoffman, R., and Rubin, B. Y. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-7. J. Immunol., 136: 4487-4495, 1986.
48. Murase, T., Holla, T., Saito, H., and Ohno, K. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood, 69:467-472, 1987.
49. Ihle, J. H. Lymphokine regulation of hematopoietic cell development. In: J. J. Oppenheim and E. M. Shevach (eds.), Immunophysiology, pp. 166-193. New York: Oxford University Press, 1990.
50. Dubois, C. M., Ruscetti, F. W., Keller, J. R., Oppenheim, J. J., Hestdal, K., Chizzonite, R., and Neta, R. In vivo interleukin 1 (IL-1) administration indirectly promotes type IIIL-I receptor expression on hematopoietic bone marrow cells: novel mechanism for the hematopoietic effects of IL-I. Blood, 78: 2841-2847, 1992.
51. Dinarello, C. A., and Mier, J. W. Current concepts: lymphokines. N. Engl. J. Med., 317: 940-945, 1987.
52. Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., and Thompson, R. C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (Lond.), 343: 341-346, 1990.